Marc Rubin

Directeur/Membre du Conseil chez CURIS, INC. Fortune : 55 738 $ au 31/08/2026

Profil

Marc Rubin is currently an Independent Director at Curis, Inc. since 2010, a Director at Soricimed Biopharma, Inc. since 2018, and a Director at The Rogosin Institute, Inc. Former roles include President & Chief Executive Officer at Titan Pharmaceuticals, Inc. from 2007 to 2009, Director at Medarex, Inc. from 2007 to 2009, Director at Titan Pharmaceuticals, Inc. from 2022 to 2023, Director at Surface Logix LLC from 2005 to 2011, Independent Director at Gemmus Pharma, Inc. from 2012 to 2014, Independent Director at Galectin Therapeutics, Inc. from 2018 to 2026, Head-Global Research & Development at Bayer Schering Pharma AG from 2006 to 2007, Senior Vice President-Global Clinical Pharmacology at GSK Plc from 1990 to 2003, and Head-Global Research & Development at Bayer Pharma AG in 2007.
Other former positions include Chairman at Schering Berlin, Inc., Director at Xequel Bio, Inc., Trustee at North Shore Medical Center, Inc., President at Berlex Pharmaceuticals, Inc., and Member-Executive Committee at Bayer HealthCare.
Education includes a doctorate from Weill Cornell Medical College conferred in 1980.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
GALECTIN THERAPEUTICS INC. 0,01%	22/09/2025	13 581 ( 0,01% )	53 645 $	31/08/2026
CURIS, INC. 0,07%	07/07/2026	1 405 ( 0,07% )	2 093 $	31/08/2026

Postes actifs de Marc Rubin

Sociétés	Poste	Début
CURIS, INC.	Directeur/Membre du Conseil	03/06/2010
The Rogosin Institute, Inc.	Directeur/Membre du Conseil	-
Soricimed Biopharma, Inc.	Directeur/Membre du Conseil	19/03/2018

Anciens postes connus de Marc Rubin

Sociétés	Poste	Fin
GALECTIN THERAPEUTICS INC.	Président	04/06/2018
TITAN PHARMACEUTICALS	Président	15/08/2022
Surface Logix LLC	Directeur/Membre du Conseil	01/01/2011
Medarex, Inc.	Directeur/Membre du Conseil	27/08/2009
TITAN PHARMACEUTICALS	Directeur Général	01/01/2009